The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

Hepatology

Volumn 48, Issue 1, 2008, Pages 88-98

  Warner, Nadia ^a   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; DIHYDROLIPOAMIDE DEHYDROGENASE; GLYCOSYLATED ALBUMIN; LAMIVUDINE; MEMBRANE PROTEIN; VIRUS DNA; VITRONECTIN;

AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA REPLICATION; GENE MUTATION; GENE SEQUENCE; GENETIC SELECTION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOP CODON; VIRION; VIRUS LOAD; VIRUS PARTICLE; WILD TYPE;

ALANINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CODON, TERMINATOR; DNA REPLICATION; GENES, DOMINANT; GLYCOSYLATION; HEPATITIS B VIRUS; HUMANS; MEMBRANE PROTEINS; MICROSCOPY, ELECTRON; MUTATION; RNA-DIRECTED DNA POLYMERASE; THREONINE; TISSUE DISTRIBUTION; TRANSFECTION; VIRAL LOAD; VIRION; VIRUS REPLICATION;

EID: 47149111970     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22295     Document Type: Article

References (37)

1. Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. HEPATOLOGY 1998;27:294-297.
2. Chien RN, Yeh CT, Wang PN, Kuo MC, Hsieh SY, Shih LY, et al. Acute leukaemia in chronic hepatitis B patients with lamivudine therapy. Int J Clin Pract 2004;58:1088-1091.
3. Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006;50:3867-3874.
4. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. HEPATOLOGY 2000;31:1318-1326.
5. Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. HEPATOLOGY 2007;45:1172-1178.
6. Qi X, Xiong S, Yang H, Miller M, Delaney WEI. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007;12:355-362.
7. Bruss V, Ganem D. Mutational analysis of hepatitis B surface antigen particle assembly and secretion. J Virol 1991;65:3813-3820.
8. Jenna S, Sureau C. Mutations in the carboxyl-terminal domain of the small hepatitis B virus envelope protein impair the assembly of hepatitis delta virus particles. J Virol 1999;73:3351-3358.
9. Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, et al. SEQHEPB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 2007;75:64-74.
10. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, et al. The rtL80I substitution in the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007;51:2285-2292.
11. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE 4th, Isom H, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. HEPATOLOGY 2003;37:27-35.
12. Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999;59:19-24.
13. Eren R, Ilan E, Nussbaum O, Lubin I, Terkieltaub D, Arazi Y, et al. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. HEPATOLOGY 2000;32:588-596.
14. Bruss V. Processing of hepatitis B virus surface proteins. Methods Mol Med 2004;95:189-198.
15. Lauer U, Weiss L, Hofschneider PH, Kekule AS. The heparitis B virus pre-S/S(t) transactivator is generated by 3′ truncations within a defined region of the S gene. J Virol 1992;66:5284-5289.
16. Natoli G, Avantaggiati ML, Balsano C, De Marzio E, Collepardo D, Elfassi E, et al. Characterization of the hepatitis B virus preS/S region encoded transcriptional transactivator. Virology 1992;187:663-670.
17. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006;44:422-431.
18. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antivital resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-693.
19. Si Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. HEPATOLOGY 2000;32:1078-1088.
20. Zoulim F. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models. Antivir Chem Chemother 2001;12(Suppl 1):131-142.
21. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 2001;34:785-791.
22. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297.
23. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. HEPATOLOGY 2007;46:254-265.
24. Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med 2004;95:125-149.
25. Wunderlich G, Bruss V. Characterization of early hepatitis B virus surface protein oligomers. Arch Virol 1996;141:1191-1205.
26. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984;52:396-402.
27. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A 1991;88:1059-1063.
28. Bruss V, Vieluf K. Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J Virol 1995;69:6652-6657.
29. Simsek E, Mehta A, Zhou T, Dwek RA, Block T. Heparitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme. J Virol 2005;79:12914-12920.
30. Rost M, Mann S, Lambert C, Doring T, Thome N, Prange R. Gamma-adaptin, a novel ubiquitin-interacting adaptor, and Nedd4 ubiquitin ligase control hepatitis B virus maturation. J Biol Chem 2006;281:29297-29308.
31. Watanabe T, Sorensen EM, Naito A, Schott M, Kim S, Ahlquist P. Involvement of host cellular multivesicular body functions in heparitis B virus budding. Proc Natl Acad Sci U S A 2007;104:10205-10210.
32. Mehta A, Lu X, Block TM, Blumberg BS, Dwek RA. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A 1997;94:1822-1827.
33. Lu X, Mehta A, Dadmarz M, Dwek R, Blumberg BS, Block TM. Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. Proc Natl Acad Sci U S A 1997;94:2380-2385.
34. Lu X, Mehta A, Dwek R, Butters T, Block T. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virology 1995; 213:660-665.
35. Sureau C, Fournier-Wirth C, Maurel P. Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virus. J Virol 2003;77:5519-5523.
36. Wang CJ, Sung SY, Chen DS, Chen PJ. N-linked glycosylation of hepatitis B surface antigens is involved but not essential in the assembly of hepatitis delta virus. Virology 1996;220:28-36.
37. Lambert C, Prange R. Posttranslational N-glycosylation of the hepatitis B virus large envelope protein. Virol J 2007;4:45.